StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

Alaunos Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Alaunos Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$4.06M. For fiscal 2025 it was -$4.23M. The highest annual figure on record is -$4.23M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.23M–
FY2024Dec 31, 2024-$4.81M–
FY2023Dec 31, 2023-$34.27M–
FY2022Dec 31, 2022-$35.11M–
FY2021Dec 31, 2021-$77.55M–
FY2020Dec 31, 2020-$80.36M–
FY2019Dec 31, 2019-$57.86M–
FY2018Dec 31, 2018-$53.91M–
FY2017Dec 31, 2017-$53.49M–
FY2016Dec 31, 2016-$165.31M–
FY2015Dec 31, 2015-$120.10M–
FY2014Dec 31, 2014-$43.50M–
FY2013Dec 31, 2013-$57.71M–
FY2012Dec 31, 2012-$102.17M–
FY2011Dec 31, 2011-$71.40M–
FY2010Dec 31, 2010-$24.55M–
FY2009Dec 31, 2009-$12.12M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$952.00K–
Q1 FY2026Mar 31, 2026-$1.01M–
Q4 FY2025Dec 31, 2025-$907.00K–
Q3 FY2025Sep 30, 2025-$1.19M–
Q2 FY2025Jun 30, 2025-$1.04M–
Q1 FY2025Mar 31, 2025-$1.09M–
Q4 FY2024Dec 31, 2024-$755.00K–
Q3 FY2024Sep 30, 2024-$1.15M–
Q2 FY2024Jun 30, 2024-$1.17M–
Q1 FY2024Mar 31, 2024-$1.74M–
Q4 FY2023Dec 31, 2023-$7.95M–
Q3 FY2023Sep 30, 2023-$8.66M–
Q2 FY2023Jun 30, 2023-$7.98M–
Q1 FY2023Mar 31, 2023-$9.67M–
Q4 FY2022Dec 31, 2022-$8.52M–
Q3 FY2022Sep 30, 2022-$8.26M–
Q2 FY2022Jun 30, 2022-$9.23M–
Q1 FY2022Mar 31, 2022-$9.09M–
Q4 FY2021Dec 31, 2021-$11.05M–
Q1 FY2021Jun 30, 2021-$44.20M–
Q4 FY2020Dec 31, 2020-$22.77M–
Q3 FY2020Sep 30, 2020-$20.32M–
Q2 FY2020Jun 30, 2020-$18.61M–
Q1 FY2020Mar 31, 2020-$18.66M–
Q4 FY2019Dec 31, 2019-$16.04M–
Q3 FY2019Sep 30, 2019-$13.45M–
Q2 FY2019Jun 30, 2019-$14.75M–
Q1 FY2019Mar 31, 2019-$13.62M–
Q4 FY2018Dec 31, 2018-$12.76M–
Q3 FY2018Sep 30, 2018-$12.57M–
Q2 FY2018Jun 30, 2018-$12.38M–
Q1 FY2018Mar 31, 2018-$16.20M–
Q4 FY2017Dec 31, 2017-$13.44M–
Q3 FY2017Sep 30, 2017-$13.08M–
Q2 FY2017Jun 30, 2017-$13.01M–
Q1 FY2017Mar 31, 2017-$13.97M–
Q4 FY2016Dec 31, 2016-$11.11M–
Q3 FY2016Sep 30, 2016-$10.91M–
Q2 FY2016Jun 30, 2016-$131.24M–

More Alaunos Therapeutics figures

See a number that looks wrong?